scholarly journals Localized Relapse of Primary Plasma Cell Leukaemia in the Central Nervous System

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
Christian W. Eskelund ◽  
Niels Frost Andersen
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Plasma Cell ◽  
Poor Prognosis ◽  
Systemic Disease ◽  
Cell Leukaemia ◽  
Cns Involvement ◽  
Aggressive Form ◽  
Plasma Cell Leukaemia ◽  
The Central Nervous System

Primary plasma cell leukaemia (pPCL) is a rare and aggressive form of plasma cell malignancies with a very poor prognosis. Compared to other plasma cell malignancies the tendency to extramedullary spread is increased; however central nervous system (CNS) involvement is rare and only reported in few cases. We report the case of a 61-year-old man who was diagnosed with pPCL and achieved a complete remission after autologous stem cell transplantation but had a relapse in the CNS without systemic disease.

Solitary pituitary sarcoidosis with normal endocrine function

2008 ◽  
Vol 108 (3) ◽  
pp. 591-594 ◽  
Author(s):  
Promod Pillai ◽  
Abhik Ray-Chaudhury ◽  
Mario Ammirati ◽  
E. Antonio Chiocca
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Biopsy Specimen ◽  
English Literature ◽  
Systemic Disease ◽  
Definitive Diagnosis ◽  
Endocrine Function ◽  
Granulomatous Disease ◽  
Cns Involvement ◽  
The Central Nervous System

✓ Sarcoidosis is a multisystemic granulomatous disease characterized by noncaseating epithelioid granulomata that affects the lung in over 90% of patients and the central nervous system (CNS) in 5–9%. Neurosarcoidosis often occurs as multifocal meningeal and parenchymal lesions, and its diagnosis is particularly difficult in the absence of concomitant systemic disease. Hypothalamic-pituitary sarcoidosis occurs in fewer than 10% of patients with neurosarcoidosis and has been previously reported in association with profound endocrinological dysfunction. The authors report the case of a patient with isolated pituitary sarcoidosis who was first evaluated for visual symptoms and showed no preoperative endocrinological dysfunction or evidence of multisystemic or other CNS involvement. To the authors' knowledge, only 1 other such presentation is previously reported in the English literature. Such presentations are diagnostically and therapeutically challenging, and definitive diagnosis requires obtaining a biopsy specimen of the lesion with histological proof of noncaseating epithelioid granuloma, as well as the exclusion of other possible entities.

scholarly journals Treatment of secondary central nervous system involvement in systemic aggressive B cell lymphoma using R-MIADD chemotherapy: a single-center study

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yuchen Wu ◽  
Xuefei Sun ◽  
Xueyan Bai ◽  
Jun Qian ◽  
Hong Zhu ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
Central Nervous System Lymphoma ◽  
Progression Free Survival ◽  
B Cell Lymphoma ◽  
High Dose ◽  
Cns Involvement ◽  
The Central Nervous System ◽  
Secondary Central Nervous System

Abstract Background Secondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma. Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined. Methods We conducted a retrospective study to assess the feasibility of an R-MIADD (rituximab, high-dose methotrexate, ifosfamide, cytarabine, liposomal formulation of doxorubicin, and dexamethasone) regimen for SCNSL patients. Results Nineteen patients with newly diagnosed CNS lesions were selected, with a median age of 58 (range 20 to 72) years. Out of 19 patients, 11 (57.9%) achieved complete remission (CR) and 2 (10.5%) achieved partial remission (PR); the overall response rate was 68.4%. The median progression-free survival after CNS involvement was 28.0 months (95% confidence interval 11.0–44.9), and the median overall survival after CNS involvement was 34.5 months. Treatment-related death occurred in one patient (5.3%). Conclusions These single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL, further investigation is warranted.

MM-340: Plasma Cell Neoplasm in the Central Nervous System: A Case Report

2021 ◽  
Vol 21 ◽  
pp. S437-S438
Author(s):  
Carine Ribeiro Franzon ◽  
Andressa Oliveira Martin Wagner ◽  
Annelise Correa Wengerkievicz Lopes ◽  
Douglas Gebauer Bona ◽  
Talita Bertazzo Schmitz
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Plasma Cell ◽  
Plasma Cell Neoplasm ◽  
System A ◽  
Cell Neoplasm ◽  
The Central Nervous System

scholarly journals Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system

2019 ◽  
Vol 59 (3) ◽  
pp. 135-139
Author(s):  
Takayuki Murase ◽  
Atsushi Inagaki ◽  
Ayako Masaki ◽  
Keiichiro Fujii ◽  
Tomoko Narita ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Plasma Cell ◽  
Plasma Cell Myeloma ◽  
The Central Nervous System

Multiple Plasma Cell Granulomas of the Central Nervous System

Neurosurgery ◽  
1994 ◽  
Vol 35 (4) ◽  
pp. 744-747 ◽  
Author(s):  
John Hsiang ◽  
David Moorhouse ◽  
David Barba
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Plasma Cell ◽  
The Central Nervous System

scholarly journals Frequency and Severity of Central Nervous System Lesions in Hemophagocytic Lymphohistiocytosis

Blood ◽  
1997 ◽  
Vol 89 (3) ◽  
pp. 794-800 ◽  
Author(s):  
Elie Haddad ◽  
Maria-Luisa Sulis ◽  
Nada Jabado ◽  
Stephane Blanche ◽  
Alain Fischer ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Disease Progression ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Systemic Disease ◽  
Neurological Symptoms ◽  
Treatment Modalities ◽  
Remission Induction ◽  
Cns Involvement ◽  
Cns Disease

Abstract We have retrospectively assessed the neurological manifestations in 34 patients with hemophagocytic lymphohistiocytosis (HLH) in a single center. Clinical, radiological, and cerebrospinal fluid (CSF ) cytology data were analyzed according to treatment modalities. Twenty-five patients (73%) had evidence of central nervous system (CNS) disease at time of diagnosis, stressing the frequency of CNS involvement early in the time course of HLH. Four additional patients who did not have initial CNS disease, who did not die early from HLH complications, and who were not transplanted, also developed a specific CNS disease. Therefore, all surviving and nontransplanted patients had CNS involvement. Initially, CNS manifestations consisted of isolated lymphocytic meningitis in 20 patients and meningitis with clinical and radiological neurological symptoms in nine patients. For these nine patients, neurological symptoms consisted of seizures, coma, brain stem symptoms, or ataxia. The outcome of patients treated by systemic and intrathecal chemotherapy and/or immunosuppression exclusively (n = 16) was poor, as all died following occurrence of multiple relapses or CNS disease progression in most cases. Bone marrow transplantation (BMT) from either an HLA identical sibling (n = 6) or haplo identical parent (n = 3) was performed in nine patients, once first remission of CNS and systemic disease was achieved. Seven are long-term survivors including three who received an HLA partially identical marrow. All seven are off treatment with normal neurological function and cognitive development. In four other patients, BMT performed following CNS relapses was unsuccessful. Given the frequency and the poor outcome of CNS disease in HLH, BMT appears, therefore, to be the only available treatment procedure that is capable of preventing HLH CNS disease progression and that can result in cure when performed early enough after remission induction.

Sign in / Sign up

Export Citation Format

Share Document